Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galiximab for Relapsed/Refractory Hodgkin Lymphoma
NCT00516217Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2008
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of galiximab in Hodgkin lymphoma (HL), sponsored by Cancer and Leukemia Group B. Started Jun 2008; status: completed.
02
Drugs
galiximab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00516217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516217.